| n = 152 | Overall % | |
|---|---|---|
| Mean age, years, (range) | 51.5 (32-87) | |
| Mean observation period, months, (range) | 64.7 (9.7-119.0) | |
| Menopausal status | ||
| Premenopausal | 75 | 49% |
| Postmenopausal | 77 | 51% |
| Chemotherapy | ||
| Yes | 127 | 84% |
| Neoadjuvant | (47) | (31%) |
| Postoperative | (80) | (53%) |
| No | 25 | 16% |
| Preoperative endocrine therapy | 2 | 1% |
| Types of chemotherapy | ||
| Anthracyclines and taxane | 106 | 70% |
| Anthracycline only | 3 | 2% |
| Taxane only | 18 | 12% |
| Postoperative endocrine therapy | ||
| Yes | 150 | 99% |
| (Tamoxifen) | (76) | (50%) |
| (Anastrozole) | (42) | (27%) |
| (Letrozole) | (28) | (18%) |
| (Exemestane) | (4) | 3% |
| No | 2 | 1% |
| LHRH agonist | 15 | 10% |
| Stage | ||
| Stage IIA | 25 | 16% |
| Stage IIB | 33 | 22% |
| Stage IIIA | 66 | 43% |
| Stage IIIB | 1 | 1% |
| Stage IIIC | 27 | 18% |
| Median invasive diameter, cm (range) | 2.8 (0.7-26.5) | |
| Invasive diameter ≥5 cm | 55 | 36% |
| Median lymph node metastases (range) | 3 (137) | |
| Four or more lymph node metastases | 68 | 44% |
| pCR after NAC | 3 | 7% |
| Nuclear Grade | ||
| 1, 2 | 56 | 37% |
| 3 | 96 | 63% |
| Ki67 | ||
| Ki67 ≧ 20% | 39 | 26% |
| Ki67 < 20% | 90 | 59% |
| unknown | 24 | 16% |
| Progeterone receptor | ||
| Positive | 126 | 83% |
| Negative | 26 | 17% |
| Cohort | ||
| 1 | 152 | 100% |
| (High) | (39) | (26%) |
| (Low) | (90) | (59%) |
| (Unknown) | (36) | (24%) |
| 2 | 0 | |
| n =152 | % | |
|---|---|---|
| IDFS Event | 30 | 20% |
| Patients with invasive disease, first recurrence | 27 (18%) | 18% |
| (Local/regional recurrence) | (6) | (4%) |
| (Distant recurrence) | (19) | (13%) |
| (Contralateral recurrence) | (0) | |
| (Second primary neoplasm) | (5) | (3%) |
| Death from any cause without invasive disease | 3 | 2% |
| Median time to IDFS event, months（range） | 60 (3.8119) | |
| DRFS event | 19 | 13% |
| Median time to DRFS event, months（range） | 34.7 (3.9105) | |
| Bone | 11 | 7% |
| Liver | 5 | 3% |
| Lung | 5 | 3% |
| Brain | 1 | 0.7% |
| Lymph node | 3 | 2% |
| Pleura | 0 | |
| Central nervous system | 0 | |
| Soft tissue | 0 | |
| Skin | 0 | |
| Peritoneum | 0 | |
| Other | 1 | 0.7% |
| Death from any cause without | 3 | 2% |
| Distant recurrence | ||
| Final Outcomes | ||
| Survival | 143 | 91% |
| Death | 9 | 6% |
| (breast cancer) | (5) | (3%) |
| IDFS events | Yes (n = 30) | No (n = 122) | P value |
|---|---|---|---|
| Chemotherapy | 0.17 | ||
| Yes | 22 (73%) | 104 (85%) | |
| No | 8 (27%) | 18 (15%) | |
| Menopausal | |||
| Premenopausal | 12 (40%) | 63 (52%) | 0.31 |
| Postmenopausal | 18 (60%) | 59 (48%) | |
| Lymph Node Metastasis | |||
| ≤3 | 13 (43%) | 70 (57%) | 0.22 |
| >4 | 17 (57%) | 52 (43%) | |
| NG | |||
| NG1, 2 | 14 (47%) | 42 (34%) | 0.29 |
| NG3 | 16 (53%) | 80 (66%) | |
| Diameter | |||
| <5cm | 15 (50%) | 40 (33%) | 0.09 |
| ≧ 5cm | 15 (50%) | 82 (67%) | |
| Ki-67 | |||
| <20% | 10 (33%) | 29 (24%) | 0.22 |
| ≧20% | 14 (47%) | 76 (62%) | |
| Unknown | 6 (20%) | 17 (14%) | |
| Present Study (n = 152) | MonarchE Study (n = 2,808) | |
|---|---|---|
| Menopausal | ||
| Premenopausal | 75 (49%) | 1,221 (43.5%) |
| Postmenopausal | 77 (51%) | 1,587 (56.5%) |
| Chemotherapy | ||
| Yes | 127 (84%) | 2,681 (95.5%) |
| (Neoadjuvant) | 47 (31%) | 1,039 (37.0%) |
| (Postoperative) | 80 (53 %) | 1,642 (58.5%) |
| No | 25 (16%) | 127 (4.5%) |
| Types of Chemotherapy | ||
| Anthracyclines and taxane | 106 (70%) | 2,349 (83.7%) |
| Anthracycline only | 3 (2%) | 151 (5.3%) |
| Taxane only | 18 (12%) | 217 (7.7%) |
| Postoperative Endocrine Therapy | ||
| Yes | 150 (99%) | 2,808 (100%) |
| (Tamoxifen) | 76 (50%) | 857 (30.7%) |
| (Anastrozole) | 42 (27%) | 611 (21.9%) |
| (Letrozole) | 28 (18 %) | 1,092 (39.1%) |
| (Exemestane) | 4 (3%) | 225 (8.1%) |
| No | 2 (1%) | 0 |
| LHRH agonist | 15 (10%) | 606 (21.7%) |
| Stage | ||
| Stage ⅠA | 0 | 2 (0.1%) |
| Stage Ⅱ | 58 (38%) | 712 (25.4%) |
| Stage Ⅲ | 94 (62%) | 2,081 (74.5%) |
| Invasive diameter 5 cm or more | 55 (36%) | 610 (21.7%) |
| Lymph node metastasis ≧ 4 | 68 (44%) | 1,680 (59.8%) |
| Ki67 ≧ 20% | 39 (26%) | 953 (34%) |
| Ki67 < 20% | 90 (59%) | 1,855 (66%) |
| Premenopausal (n = 75) | Postmenopausal (n = 77) | P value | |
|---|---|---|---|
| Age | 46.1 ± 6.8 | 65.6 ± 9.7 | < 0.01 |
| Stage | |||
| Stage Ⅱ | 31 (41%) | 27 (35%) | 0.51 |
| Stage Ⅲ | 44 (59%) | 50 (65%) | |
| Diameter | |||
| <5 cm | 45 | 52 | 0.40 |
| >5 cm | 30 | 25 | |
| Lymph Node Metastasis | |||
| <3 | 45 (60%) | 38 (49%) | 0.20 |
| ≥4 | 30 (40%) | 39 (51%) | |
| NG | |||
| NG1, 2 | 32 (43%) | 24 (31%) | 0.18 |
| NG3 | 43 (57%) | 53 (67%) | |
| Chemotherapy | |||
| Yes | 70 (93%) | 56 (73%) | <0.01 |
| Neoadjuvant | |||
| Adjuvant | |||
| No | 5 (7%) | 21 (27%) | |
| Postoperative Endocrine Therapy | |||
| Yes | Tamoxifen vs. Aromataze inhibitor < 0.01 |
||
| (Tamoxifen) | 72 (96%) | 4 (5%) | |
| (Anastrozole) | 0 | 42 (55%) | |
| (Letrozole) | 2 (3%) | 26 (34%) | |
| (Exemestane) | 0 | 4 (5%) | |
| No | 1 (1%) | 1 (1%) | |
| LH-RH agonist | 10 (13%) | 0 | <0.07 |
